SLE患者外周血单核细胞CD36水平与血脂紊乱的关系
|
摘要
目的通过检测系统性红斑狼疮(systemic lupus erythematosus,SLE)患者及表观健康自愿者外周血单核细胞CD36的表达及其血清脂蛋白水平,探讨SLE患者单核细胞CD36表达对脂代谢的影响,为临床早期提示SLE并发心血管疾病风险提供依据。方法利用流式细胞仪检测SLE患者30例和健康体检者31例外周血单核细胞CD36强度,采用生化仪测定血清脂蛋白水平,统计分析患者与健康对照组间单核细胞CD36表达平均荧光强度与血清脂蛋白浓度差异性,及SLE患者CD36与脂蛋白间的相关性。结果 SLE患者单核细胞CD36表达低于健康对照组(|Z|=4.198,P=0.000),TG,VLDLC和apoB100高于对照组(|Z|=4.603,P=0.000;|Z|=3.620,P=0.001;|Z|=2.208,P=0.027),HDLC与apoA1低于对照组(|Z|=3.751,P=0.000;|Z|=3.918,P=0.000),差异均有统计学意义;TC和LDLC在两组间差异无统计学意义(|Z|=0.159,P=0.874;|Z|=0.476,P=0.634)。SLE患者单核细胞CD36表达强度与血清脂蛋白水平无显著相关性(P>0.05)。结论系统性红斑狼疮患者外周血单核细胞CD36表达相较健康人群降低,其可能是SLE心血管疾病高发的独立风险因素。
Objective To explore the relationship between expression level of CD36 on peripheral monocytes and dyslipidemia,and evaluate the clinical significance in prediction risk of cardiovascular disease in patients with systemic lupus erythematosus(SLE).Methods Monocytes CD36 and serum lipoprotein levels were determined in 30 patients with SLE and 31 cases healthy volunteers.Compared CD36 of monocytes expression intensity and lipoprotein concentration in SLE patients and health controls.Meanwhile,the correlation between CD36 and lipoprotein was analyzed in SLE patients.Results The CD36 expression on monocytes in patients with SLE was significantly lower than that in the control group(|Z|=4.198,P=0.000).TG,VLDLC and apoB100 levels of SLE patients were significantly higher than the control group(|Z|=4.603,P=0.000.|Z|=3.620,P=0.001.|Z|=2.208,P=0.027).HDLC and apoA1 levels of SLE patients were significantly lower than the control group(|Z|=3.751,P=0.000.|Z|=3.918,P=0.000).There were no statistically significant difference in TC and LDLC between SLE patients and healthy volunteers(|Z|=0.159,0.476,P=0.874,0.634).There was no significant correlation between CD36 expression intensity and serum lipoprotein levels in SLE patients(P>0.05).ConclusionThe expression of CD36 on peripheral blood monocytes of patients with SLE was lower than that of healthy people,and the decrease of CD36 expression on monocytes may be an independent risk factor for cardiovascular disease in SLE.
Objective To explore the relationship between expression level of CD36 on peripheral monocytes and dyslipidemia,and evaluate the clinical significance in prediction risk of cardiovascular disease in patients with systemic lupus erythematosus(SLE).Methods Monocytes CD36 and serum lipoprotein levels were determined in 30 patients with SLE and 31 cases healthy volunteers.Compared CD36 of monocytes expression intensity and lipoprotein concentration in SLE patients and health controls.Meanwhile,the correlation between CD36 and lipoprotein was analyzed in SLE patients.Results The CD36 expression on monocytes in patients with SLE was significantly lower than that in the control group(|Z|=4.198,P=0.000).TG,VLDLC and apoB100 levels of SLE patients were significantly higher than the control group(|Z|=4.603,P=0.000.|Z|=3.620,P=0.001.|Z|=2.208,P=0.027).HDLC and apoA1 levels of SLE patients were significantly lower than the control group(|Z|=3.751,P=0.000.|Z|=3.918,P=0.000).There were no statistically significant difference in TC and LDLC between SLE patients and healthy volunteers(|Z|=0.159,0.476,P=0.874,0.634).There was no significant correlation between CD36 expression intensity and serum lipoprotein levels in SLE patients(P>0.05).ConclusionThe expression of CD36 on peripheral blood monocytes of patients with SLE was lower than that of healthy people,and the decrease of CD36 expression on monocytes may be an independent risk factor for cardiovascular disease in SLE.
引文
[1]Atta AM,Silva JPCG,Santiago MB,et al.Clinical and laboratory aspects of dyslipidemia in Brazilian women with systemic lupus erythematosus[J].Clin Rheumatol,2018 Mar 8.doi:100.1007/s10067-018-4051-0(Epub ahead of print).
[2]Choromańska B1,Mysliwiec P,Choromańska K,et al.The role of CD36receptor in the pathogenesis of atherosclerosis[J].Adv Clin Exp Med,2017,26(4):717-722.
[3]Reiss AB,Wan DW,Anwar K,et al.Enhanced CD36scavenger receptor expression in THP-1human monocytes in the presence of lupus plasma:linking autoimmunity and atherosclerosis[J].Experimental Biology and Medicine,2009,234(3):354-360.
[4]Yuan JS,Li L,Wang ZY,et al.Dyslipidemia in patients with systemic lupus erythematosus:Association with disease activity and B-type natriuretic peptide levels[J].Biomedical Reports,2016,4(1):68-72.
[5]Sajjad S,Farman S,Saeed MA,et al.Frequency of dyslipidemia in patients with lupus nephritis[J].Pakistan Journal of Medical Sciences,2017,33(2):358-362.
[6]Skaggs BJ,Hahn BH,McMahon M.Accelerated atherosclerosis in patients with SLE-mechanisms and management[J].Nature Reviews Rheumatology,2012,8(4):214-223.
[7]Sinicato NA,da Silva Cardoso PA,Appenzeller S.Risk factors in cardiovascular disease in systemic lupus erythematosus[J].Current Cardiology Reviews,2013,9(1):15-19.
[8]Pego-Reigosa JM,Rua-Figueroa I,Lopez-Longo FJ,et al.Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus[J].Lupus,2015,24(7):720-729.
[9]Gaal K,Tarr T,Lorincz H,et al.High-density lipopoprotein antioxidant capacity,subpopulation distribution and paraoxonase-1activity in patients with systemic lupus erythematosus[J].Lipids in Health and Disease,2016,15(1):60.
[10]Kato M,Atsumi T,Oku K,et al.The involvement of CD36in monocyte activation by antiphospholipid antibodies[J].Lupus,2013,22(8):761-771.
[11]Silverstein RL,Li W,Park YM,et al.Mechanisms of cell signaling by the scavenger receptor CD36:implications in atherosclerosis and thrombosis[J].Transactions of the American Clinical and Climatological Association,2010,121(121):206-220.
[12]Boyer JF,Balard P,Authier H,et al.Tumor necrosis factor alpha and adalimumab differentially regulate CD36expression in human monocytes[J].Arthritis Res Ther,2007,9(2):R22.
[13]Febbraio M,Abumrad NA,Hajjar DP,et al.A null mutation in murine CD36reveals an important role in fatty acid and lipoprotein metabolism[J].The Journal of Biological Chemistry,1999,274(27):19055-19062.
[14]Moreira ME,Barcinski MA.Apoptotic cell and phagocyte interplay:recognition and consequences in different cell systems[J].Anais da Academia Brasileira de Ciencias,2004,76(1):93-115.
[15]Ramos-Arellano LE,Munoz-Valle JF,De la CruzMosso U,et al.Circulating CD36and oxLDL levels are associated with cardiovascular risk factors in young subjects[J].BMC Cardiovascular Disorders,2014,14(1):54.
[16]Febbraio M,Podrez EA,Smith JD,et al.Targeted disruption of the class B scavenger receptor CD36protects against atherosclerotic lesion development in mice[J].The Journal of Clinical Investigation,2000,105(8):1049-1056.
[2]Choromańska B1,Mysliwiec P,Choromańska K,et al.The role of CD36receptor in the pathogenesis of atherosclerosis[J].Adv Clin Exp Med,2017,26(4):717-722.
[3]Reiss AB,Wan DW,Anwar K,et al.Enhanced CD36scavenger receptor expression in THP-1human monocytes in the presence of lupus plasma:linking autoimmunity and atherosclerosis[J].Experimental Biology and Medicine,2009,234(3):354-360.
[4]Yuan JS,Li L,Wang ZY,et al.Dyslipidemia in patients with systemic lupus erythematosus:Association with disease activity and B-type natriuretic peptide levels[J].Biomedical Reports,2016,4(1):68-72.
[5]Sajjad S,Farman S,Saeed MA,et al.Frequency of dyslipidemia in patients with lupus nephritis[J].Pakistan Journal of Medical Sciences,2017,33(2):358-362.
[6]Skaggs BJ,Hahn BH,McMahon M.Accelerated atherosclerosis in patients with SLE-mechanisms and management[J].Nature Reviews Rheumatology,2012,8(4):214-223.
[7]Sinicato NA,da Silva Cardoso PA,Appenzeller S.Risk factors in cardiovascular disease in systemic lupus erythematosus[J].Current Cardiology Reviews,2013,9(1):15-19.
[8]Pego-Reigosa JM,Rua-Figueroa I,Lopez-Longo FJ,et al.Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus[J].Lupus,2015,24(7):720-729.
[9]Gaal K,Tarr T,Lorincz H,et al.High-density lipopoprotein antioxidant capacity,subpopulation distribution and paraoxonase-1activity in patients with systemic lupus erythematosus[J].Lipids in Health and Disease,2016,15(1):60.
[10]Kato M,Atsumi T,Oku K,et al.The involvement of CD36in monocyte activation by antiphospholipid antibodies[J].Lupus,2013,22(8):761-771.
[11]Silverstein RL,Li W,Park YM,et al.Mechanisms of cell signaling by the scavenger receptor CD36:implications in atherosclerosis and thrombosis[J].Transactions of the American Clinical and Climatological Association,2010,121(121):206-220.
[12]Boyer JF,Balard P,Authier H,et al.Tumor necrosis factor alpha and adalimumab differentially regulate CD36expression in human monocytes[J].Arthritis Res Ther,2007,9(2):R22.
[13]Febbraio M,Abumrad NA,Hajjar DP,et al.A null mutation in murine CD36reveals an important role in fatty acid and lipoprotein metabolism[J].The Journal of Biological Chemistry,1999,274(27):19055-19062.
[14]Moreira ME,Barcinski MA.Apoptotic cell and phagocyte interplay:recognition and consequences in different cell systems[J].Anais da Academia Brasileira de Ciencias,2004,76(1):93-115.
[15]Ramos-Arellano LE,Munoz-Valle JF,De la CruzMosso U,et al.Circulating CD36and oxLDL levels are associated with cardiovascular risk factors in young subjects[J].BMC Cardiovascular Disorders,2014,14(1):54.
[16]Febbraio M,Podrez EA,Smith JD,et al.Targeted disruption of the class B scavenger receptor CD36protects against atherosclerotic lesion development in mice[J].The Journal of Clinical Investigation,2000,105(8):1049-1056.